IL7 and glioma: In addition, efineptakin alfa (NT-17/GX-17), the only next-generation drug of IL-7 developed by NeoImmune Tech (Figure 2), and the world’s first and only long-acting recombinant human IL-7 (rhIL-7), can augment cytotoxic CD8+ T cells expansion, increase IFN-γ production, decrease the number of Treg cells and prolong the survival of C57BL/6 mice glioma models (140).